Enhancing the QUAlity and Transparency Of health Research
Use your browser's Back button to return to your search results
|Reporting guideline provided for?
(i.e. exactly what the authors state in the paper)
|Tumour marker prognostic studies|
|Full bibliographic reference||McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387-391.|
(full-text if available)
|The reporting checklist for tumour marker prognostic studies is available at: REMARK checklist|
|Explanation and elaboration papers||Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.
BMC Med. 2012;10:51. PMID: 22642691
PLoS Med. 9(5):e1001216. Link to full-text
|Reporting guideline acronym||REMARK|
|Study design||Diagnostic and prognostic studies, Observational studies|
|Clinical area||Genetics, Oncology|
|Applies to the whole report or to individual sections of the report?||Whole report|
|Record last updated on||October 13, 2016|
|Diagnostic / prognostic studies||STARD||TRIPOD|
|Quality improvement studies||SQUIRE|
|Animal pre-clinical studies||ARRIVE|
Some reporting guidelines are also available in languages other than English. Find out more in our Translations section.
For information about Library scope and content, identification of reporting guidelines and inclusion/exclusion criteria please visit About the Library.
Visit our Help page for information about searching for reporting guidelines and for general information about using our website.
Our full catalogue of reporting guidelines is available to download as a PDF: Reporting Guideline Catalogue May 2014.